Harding Loevner’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.8M Buy
+180,954
New +$29.1M 0.28% 49
2022
Q4
– Sell
-767
Closed -$81K – 133
2022
Q3
$81K Sell
767
-43
-5% -$4.36K ﹤0.01% 90
2022
Q2
$79K Hold
810
– – ﹤0.01% 90
2022
Q1
$61K Buy
810
+33
+4% +$2.8K ﹤0.01% 95
2021
Q4
$66K Buy
777
+215
+38% +$19.8K ﹤0.01% 102
2021
Q3
$54K Hold
562
– – ﹤0.01% 99
2021
Q2
$55K Hold
562
– – ﹤0.01% 105
2021
Q1
$55K Hold
562
– – ﹤0.01% 110
2020
Q4
$54K Hold
562
– – ﹤0.01% 106
2020
Q3
$54K Buy
562
+306
+120% +$35.4K ﹤0.01% 137
2020
Q2
$31K Hold
256
– – ﹤0.01% 117
2020
Q1
$22K Buy
+256
New +$25.1K ﹤0.01% 121

Other funds holding NBIX

Harding Loevner's NBIX Position: Q3 2026 in Review

Harding Loevner opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 180,954 shares worth $25.8M. The stake represents 0.28% of the portfolio and ranks #49 among its holdings. This is a return to the name: Harding Loevner previously reported a position in NBIX as recently as Q3 2022.

Harding Loevner first reported a position in NBIX in Q1 2020 and has held it in 12 quarters since. 766 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Harding Loevner held 180,954 shares of Neurocrine Biosciences worth $25.8M as of Q3 2026.
  • Neurocrine Biosciences was a new Harding Loevner position in Q3 2026.
  • Neurocrine Biosciences made up 0.28% of Harding Loevner's portfolio in Q3 2026, its #49 holding.
  • Harding Loevner first reported a position in Neurocrine Biosciences in Q1 2020 and has held it in 12 quarters since.
  • 766 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Harding Loevner's 13F filing for Q3 2026, filed 16 Nov 2026.